Imnovid

Pomalidomide, the active ingredient in Imnovid, is an immunomodulatory agent presented as an oral tablet for oral use. It is indicated for the treatment of relapsed/refractory multiple myeloma in adult patients who have received prior therapies. GNH USA supplies Imnovid as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Imnovid is an immunomodulatory drug used in the management of plasma‑cell malignancies, specifically multiple myeloma. - Relapsed/refractory multiple myeloma: improves disease control and extends progression‑free survival when used after prior therapies.

Adverse reactions to pomalidomide can vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Anemia: lowered red blood cell levels causing fatigue. - Fatigue: general feeling of tiredness. - Constipation: difficulty passing stools. - Nausea: upset stomach and urge to vomit. - Infections: heightened susceptibility to bacterial or viral infections.

Serious or Rare Side Effects: - Thromboembolic events: blood clots in veins or arteries. - Severe rash or skin reactions: including Stevens‑Johnson syndrome. - Elevated liver enzymes: indicating hepatic stress. - Secondary primary malignancies: emergence of new cancers. - Deep vein thrombosis or pulmonary embolism. - Severe neutropenia leading to febrile neutropenia.

Before initiating therapy, clinicians should assess patient risk factors and monitor for potential complications. - Blood count monitoring: perform regular CBC to detect neutropenia or anemia. - Thromboembolic risk assessment: evaluate history of clotting disorders and consider prophylactic anticoagulation. - Pregnancy avoidance: enforce strict contraception for women of child‑bearing potential. - Hepatic function evaluation: check liver enzymes prior to and during treatment. - Drug‑specific warnings: avoid concomitant use with known teratogens. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Pomalidomide may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase pomalidomide exposure. - Teratogenic agents: concurrent use can heighten fetal risk. - Immunosuppressants (e.g., high‑dose steroids): may amplify infection risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Anticoagulants (e.g., warfarin, DOACs): monitor for altered clotting parameters. - CYP1A2 inhibitors (e.g., fluvoxamine): may modestly increase levels. - Vaccines: live vaccines should be avoided during therapy.